{"id":49839,"date":"2022-10-20T07:01:59","date_gmt":"2022-10-20T05:01:59","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\/"},"modified":"2022-10-20T07:01:59","modified_gmt":"2022-10-20T05:01:59","slug":"approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\/","title":{"rendered":"Approval of extension of exemptions from SIX disclosure and publicity obligations"},"content":{"rendered":"
\n

ST. GALLEN, Switzerland–(BUSINESS WIRE)–Regulatory News:\n<\/p>\n

<\/a><\/p>\n

\nAD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR\n<\/p>\n

\nVifor Pharma AG (Vifor) announced today that by decision dated October 19, 2022, SIX Exchange Regulation AG (SER) has approved an extension of the various exemptions from certain disclosure and publicity obligations granted by SER to Vifor Pharma AG previously (see Vifor Pharma AG’s ad hoc announcement of August 2, 2022).\n<\/p>\n

\nThe relevant parts of the decision of SER of October 19, 2022, are as follows:\n<\/p>\n

\n“I. Die Vifor Pharma AG (Emittent) wird im Hinblick auf die geplante Dekotierung bis und mit 28. Februar 2023 von folgenden Pflichten befreit:\n<\/p>\n

\na. Ver\u00f6ffentlichung des Halbjahresberichts 2022 (Art. 49 ff. KR i.V.m. Art. 10 ff. Richtlinie Rechnungslegung [RLR] und Art. 9 Ziff. 2.01 (2) Richtlinie Regelmeldepflichten [RLRMP]);\n<\/p>\n

\nb. Ver\u00f6ffentlichung von Ad hoc-Mitteilungen (Art. 53 KR i.V.m. der Richtlinie betr. Ad hoc-Publizit\u00e4t [RLAhP]), davon ausgenommen ist die Ver\u00f6ffentlichung einer Ad hoc-Mitteilung betreffend die Bekanntgabe des Zeitpunkts der Dekotierung der Namensaktien des Emittenten, sobald dieser bestimmt ist;\n<\/p>\n

\nc. Offenlegung von Management-Transaktionen (Art. 56 KR);\n<\/p>\n

\nd. F\u00fchrung des Unternehmenskalenders (Art. 52 KR);\n<\/p>\n

\ne. Erf\u00fcllung der nachfolgend genannten Regelmeldepflichten (Art. 55 KR i.V.m. Art. 9 der Richtlinie Regelmeldepflichten [RLRMP]):\n<\/p>\n

\n– Ziff. 1.05 (\u00c4nderung des Revisionsorgans);\n<\/p>\n

\n– Ziff. 1.06 (\u00c4nderung des Bilanzstichtags);\n<\/p>\n

\n– Ziff. 1.08 (4) (\u00c4nderung Weblink zum Unternehmenskalender);\n<\/p>\n

\n– Ziff. 1.08 (5) (\u00c4nderung Weblink zu den Jahres- und Halbjahresberichten);\n<\/p>\n

\n– Ziff. 2.01 (Einreichung Finanzbeschl\u00fcsse);\n<\/p>\n

\n– Ziff. 3.05 (Beschl\u00fcsse betreffend Opting Out\/Opting Up);\n<\/p>\n

\n– Ziff. 3.06 (\u00c4nderung betreffend Vinkulierungsbestimmungen);\n<\/p>\n

\n– Ziff. 5.02 (Meldung des bedingten Kapitals).\n<\/p>\n

\nII. Die Befreiung gem\u00e4ss Ziff. I beginnt mit Ver\u00f6ffentlichung der Ad hoc-Mitteilung gem\u00e4ss den Vorgaben in Ziff. VI.\n<\/p>\n

\nIII. Der Emittent wird bis und mit 28. Februar 2023 von den Pflichten gem\u00e4ss Ziff. I befreit, sofern und soweit keiner der folgenden Tatbest\u00e4nde bis zum 28. Februar 2023 eintritt:\n<\/p>\n

\na. Eintritt eines Minderheitsaktion\u00e4rs oder mehrerer Minderheitsaktion\u00e4re in das Verfahren um Kraftloserkl\u00e4rung der Namensaktien des Emittenten nach Art. 137 des Bundesgesetzes \u00fcber die Finanzmarktinfrastrukturen und das Marktverhalten im Effekten- und Devisenhandel vom 19. Juni 2015 (Finanzmarktinfrastrukturgesetz, FinfraG) vor dem zust\u00e4ndigen Gericht;\n<\/p>\n

\nb. R\u00fcckzug der Klage um Kraftloserkl\u00e4rung der Namensaktien des Emittenten vor dem zust\u00e4ndigen Gericht durch die Kl\u00e4gerin oder durch eine Rechtsnachfolgerin;\n<\/p>\n

\nc. Abweisung der Klage um Kraftloserkl\u00e4rung der Namensaktien des Emittenten durch das zust\u00e4ndige Gericht;\n<\/p>\n

\nd. Weiterzug des Urteils des zust\u00e4ndigen Gerichts betreffend die Kraftloserkl\u00e4rung der Namensaktien des Emittenten.\n<\/p>\n

\nSollte einer der Tatbest\u00e4nde gem\u00e4ss dieser Ziffer III. Bst. a. bis d. bis zum 28. Februar 2023 eintreten, leben die Pflichten des Emittenten gem\u00e4ss Ziff. I umgehend wieder auf.\n<\/p>\n

\nIm Falle eines Wiederauflebens der Pflichten gem\u00e4ss Ziff. I, hat der Emittent den Halbjahresbericht 2022 innert sechs Wochen ab dem Tag des jeweiligen Wiederauflebens der Pflichten gem\u00e4ss Ziff. I zu publizieren und SIX Exchange Regulation AG einzureichen (Art. 50 KR i.V.m. Art. 11 ff. RLR und Art. 9 Ziff. 2.01 (2) RLRMP).”\n<\/p>\n

\nUnofficial English translation:\n<\/p>\n

\n“I. In view of the envisaged delisting, Vifor Pharma AG (Issuer) is hereby exempted from the following obligations until and including 28 February 2023:\n<\/p>\n

\na. Publication of the Half-Year Report 2022 (art. 49 et. seq. LR in conjunction with art. 10 et seq. Directive on Financial Reporting [DFR] and art. 9 no. 2.01 (2) Directive Regular Reporting Obligations [DRRO]);\n<\/p>\n

\nb. Publication of ad hoc notices (art. 53 LR in conjunction with the Directive on Ad Hoc Publicity [DAH]), with the exception of the publication of an ad hoc notice concerning the announcement of the date of delisting of the Issuer’s registered shares as soon as such date has been determined;\n<\/p>\n

\nc. Disclosure of management transactions (art. 56 LR);\n<\/p>\n

\nd. Keeping of the corporate calendar (art. 52 LR);\n<\/p>\n

\ne. Fulfillment of the following regular reporting obligations (art. 55 LR in conjunction with art. 9 DRRO):\n<\/p>\n

\n– no. 1.05 (change of external auditors);\n<\/p>\n

\n– no. 1.06 (change of balance sheet date);\n<\/p>\n

\n– no. 1.08 (4) (change of weblink to the corporate calendar);\n<\/p>\n

\n– no. 1.08 (5) (change of weblink to the annual and half-year reports);\n<\/p>\n

\n– no. 2.01 (filing of annual reports);\n<\/p>\n

\n– no. 3.05 (resolutions regarding opting out\/ opting up);\n<\/p>\n

\n– no. 3.06 (changes regarding restrictions on transferability of shares);\n<\/p>\n

\n– no. 5.02 (reporting of conditional capital).\n<\/p>\n

\nII. The exemptions pursuant to Section I shall be effective following the publication of the ad hoc notice pursuant to, and in accordance with the requirements of, Section VI.\n<\/p>\n

\nIII. The Issuer shall be exempted from the obligations pursuant to Section I until and including 28 February 2023, if none of the following events occurs by 28 February 2023:\n<\/p>\n

\na. Joinder of a minority shareholder or several minority shareholders to the proceedings for cancellation of the Issuer’s registered shares pursuant to art. 137 of the Federal Act on Financial Market Infrastructures and Market Conduct in Securities and Derivatives Trading of 19 June 2015 (Financial Market Infrastructures Act, FMIA) before the competent court;\n<\/p>\n

\nb. Withdrawal of the action for cancellation of the Issuer’s registered shares before the competent court by the plaintiff or by a legal successor;\n<\/p>\n

\nc. Dismissal of the action for cancellation of the Issuer’s registered shares by the competent court;\n<\/p>\n

\nd. The judgment of the competent court regarding the cancellation of the Issuer’s registered shares is being appealed.\n<\/p>\n

\nShould any of the events pursuant to this Section III. letter a. to d. occur until 28 February 2023, the Issuer’s obligations pursuant to Section I shall revive immediately.\n<\/p>\n

\nIn the event of a revival of the obligations pursuant to Section I, the Issuer must publish and submit to SIX Exchange Regulation AG the Half-Year Report 2022 within six weeks from the date of the respective revival of the obligations pursuant to Section I (art. 50 LR in conjunction with art. 11 et seq. DFR and art. 9 no. 2.01 (2) DRRO).”\n<\/p>\n

\nAbout CSL Vifor<\/b>\n<\/p>\n

\nCSL Vifor<\/a> is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency, dialysis and nephrology & rare disease. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).\n<\/p>\n

\nThe parent company, CSL<\/a> (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 30,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor visit, www.cslvifor.com<\/a>.\n<\/p>\n

\nForward-Looking Statements<\/span><\/b>\n<\/p>\n

\nThis announcement may contain statements that constitute forward-looking statements. The words \u201canticipate\u201d, \u201cbelieve\u201d, \u201cexpect\u201d, “estimate”, “aim”, \u201cproject\u201d, \u201cforecast\u201d, \u201cestimate\u201d, “risk”, \u201clikely\u201d, \u201cintend\u201d, \u201coutlook\u201d, \u201cshould\u201d, \u201ccould\u201d, “would”, \u201cmay\u201d, “will”, “continue”, “plan”, “probability”, “indicative”, “seek”, \u201ctarget\u201d, \u201cplan\u201d and other similar expressions are intended to identify forward-looking statements.\n<\/p>\n

\nAny such statements, opinions and estimates in this announcement speak only as of the date hereof and are based on assumptions and contingencies subject to change without notice, as are statements about market and industry trends, projections, guidance and estimates. Forward-looking statements are provided as a general guide only. The forward-looking statements in this announcement are not indications, guarantees or predictions of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of CSL and Vifor and their officers, employees, agents and advisors, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct, and may cause actual results to differ materially from those expressed or implied in such statements. You are strongly cautioned not to place undue reliance on forward-looking statements.\n<\/p>\n

\nThis announcement is not a financial product or investment advice, a recommendation to acquire or sell securities or accounting, legal or tax advice. It does not constitute an invitation or offer to apply for securities. It has been prepared without taking into account the objectives, financial or tax situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial and tax situation and needs and seek legal and taxation advice appropriate for their jurisdiction. CSL and Vifor are not licensed to provide financial product advice in respect of an investment in securities.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nCSL Vifor Media Contact<\/b>
Thomas Hutter
\n
Mobile: +41 79 957 96 73
\n
Email: media@viforpharma.com<\/a>\n<\/p>\n

\nCSL Investor Contact<\/b>
Steve McKeon
\n
Associate Director, Investor Relations
\n
CSL Limited
\n
Mobile +61 402 231 696
\n
Email: stephen.mckeon@csl.com.au<\/a>\n<\/p>\n

\nSwitzerland \/ Europe<\/b>
Martin Meier-Pfister (IRF)
\n
P: + 41 432 448 140
\n
E: meier-pfister@irf-reputation.ch<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ST. GALLEN, Switzerland–(BUSINESS WIRE)–Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma AG (Vifor) announced today that by decision dated October 19, 2022, SIX Exchange Regulation AG (SER) has approved an extension of the various exemptions from certain disclosure and publicity obligations granted by SER to Vifor Pharma AG previously (see Vifor … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49839","6":"format-standard","7":"category-industry"},"yoast_head":"\nApproval of extension of exemptions from SIX disclosure and publicity obligations - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Approval of extension of exemptions from SIX disclosure and publicity obligations - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ST. GALLEN, Switzerland–(BUSINESS WIRE)–Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma AG (Vifor) announced today that by decision dated October 19, 2022, SIX Exchange Regulation AG (SER) has approved an extension of the various exemptions from certain disclosure and publicity obligations granted by SER to Vifor Pharma AG previously (see Vifor ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-20T05:01:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221019006063\/en\/1608023\/21\/CSLVifor_CMYK_Highres_M01.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Approval of extension of exemptions from SIX disclosure and publicity obligations\",\"datePublished\":\"2022-10-20T05:01:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\\\/\"},\"wordCount\":1374,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221019006063\\\/en\\\/1608023\\\/21\\\/CSLVifor_CMYK_Highres_M01.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\\\/\",\"name\":\"Approval of extension of exemptions from SIX disclosure and publicity obligations - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221019006063\\\/en\\\/1608023\\\/21\\\/CSLVifor_CMYK_Highres_M01.jpg\",\"datePublished\":\"2022-10-20T05:01:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221019006063\\\/en\\\/1608023\\\/21\\\/CSLVifor_CMYK_Highres_M01.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221019006063\\\/en\\\/1608023\\\/21\\\/CSLVifor_CMYK_Highres_M01.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Approval of extension of exemptions from SIX disclosure and publicity obligations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Approval of extension of exemptions from SIX disclosure and publicity obligations - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\/","og_locale":"en_US","og_type":"article","og_title":"Approval of extension of exemptions from SIX disclosure and publicity obligations - Pharma Trend","og_description":"ST. GALLEN, Switzerland–(BUSINESS WIRE)–Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma AG (Vifor) announced today that by decision dated October 19, 2022, SIX Exchange Regulation AG (SER) has approved an extension of the various exemptions from certain disclosure and publicity obligations granted by SER to Vifor Pharma AG previously (see Vifor ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-20T05:01:59+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221019006063\/en\/1608023\/21\/CSLVifor_CMYK_Highres_M01.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Approval of extension of exemptions from SIX disclosure and publicity obligations","datePublished":"2022-10-20T05:01:59+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\/"},"wordCount":1374,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221019006063\/en\/1608023\/21\/CSLVifor_CMYK_Highres_M01.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\/","url":"https:\/\/pharma-trend.com\/en\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\/","name":"Approval of extension of exemptions from SIX disclosure and publicity obligations - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221019006063\/en\/1608023\/21\/CSLVifor_CMYK_Highres_M01.jpg","datePublished":"2022-10-20T05:01:59+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221019006063\/en\/1608023\/21\/CSLVifor_CMYK_Highres_M01.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221019006063\/en\/1608023\/21\/CSLVifor_CMYK_Highres_M01.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/approval-of-extension-of-exemptions-from-six-disclosure-and-publicity-obligations\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Approval of extension of exemptions from SIX disclosure and publicity obligations"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49839","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49839"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49839\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49839"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49839"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49839"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}